Compare SQM & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQM | GMAB |
|---|---|---|
| Founded | 1968 | 1999 |
| Country | Chile | Denmark |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 17.4B |
| IPO Year | 1993 | N/A |
| Metric | SQM | GMAB |
|---|---|---|
| Price | $64.39 | $31.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $49.07 | $40.40 |
| AVG Volume (30 Days) | ★ 2.0M | 1.7M |
| Earning Date | 11-18-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | N/A | ★ 132.41 |
| EPS | 1.84 | ★ 25.10 |
| Revenue | ★ $4,326,111,000.00 | $3,845,670,022.00 |
| Revenue This Year | N/A | $24.92 |
| Revenue Next Year | $22.11 | $15.97 |
| P/E Ratio | $34.82 | ★ $1.26 |
| Revenue Growth | N/A | ★ 29.57 |
| 52 Week Low | $29.36 | $17.24 |
| 52 Week High | $65.65 | $33.65 |
| Indicator | SQM | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 72.65 | 61.58 |
| Support Level | $58.00 | $31.32 |
| Resistance Level | $65.65 | $32.48 |
| Average True Range (ATR) | 2.53 | 0.61 |
| MACD | 0.51 | 0.19 |
| Stochastic Oscillator | 92.41 | 75.27 |
Sociedad Quimica y Minera de Chile is a Chilean commodities producer with significant operations in lithium (primarily used in batteries for electric vehicles and energy storage systems), specialty and standard potassium fertilizers, iodine (primarily used in X-ray contrast media), and solar salts. The company extracts these materials through its high-quality salt brine deposits and caliche ore. SQM also sells lithium concentrate from a joint venture hard rock lithium project in Australia and expanding its lithium refining assets in China.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.